N/A
Completed N=45
Investigation of the Role of Pictorial Asthma Action Plans to Promote Self-management in Rural Youth With Asthma
Source: ClinicalTrials.gov NCT03187119 ↗Enrolled (actual)
45
Serious AEs
0.0%
Results posted
Oct 2021
Primary outcomePrimary: The Asthma Action Plan Knowledge Interview (AAPKI)-Child — 76.11; 61.40; 77.08; 62.09 Average Percent Correct — p=0.42
Summary
The aim of this study is to investigate the potential benefit of Pictorial versus Written Asthma Action Plans (AAPs) to support asthma management among young people with persistent asthma. Participants will be randomly allocated to the Pictorial or Written AAP group and followed up over a 6-month period. Qualitative and quantitative data will be collected from young people, parents and clinical teams involved in recruitment to assess the feasibility and acceptability of the Pictorial AAP (PAAP) software developed for this study, the PAAPs produced by the software, and the study procedures.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Asthma Action Plan Knowledge Interview (AAPKI)-Child |
76.11; 61.40; 77.08; 62.09 | 0.42 |
| PRIMARY The Asthma Action Plan Knowledge Interview (AAPKI)-Parent |
74.44; 69.59; 63.89; 65.28 | 0.31 |
| PRIMARY Asthma Control Test |
19; 11; 3; 11; 17; 16 | 0.06 |
| PRIMARY Adherence to Daily Controller Inhaler |
50; 75; 50; 50; 50; 100 | .002 sig |
| PRIMARY Lung Function-FEV1 |
2.60; 2.39; 2.68; 2.66 | 0.18 |
| PRIMARY Lung Function- FEF 25-75 |
2.88; 2.58; 2.76; 2.61 | — |
| SECONDARY Satisfaction With Asthma Action Plan-Caregiver |
3.64; 3.67; 3.60; 3.68 | 0.74 |
| SECONDARY Satisfaction With Asthma Action Plan-Patient |
3.65; 3.53; 3.77; 3.48 | 0.08 |
Eligibility Criteria
Inclusion Criteria
- age 8-17 years
- new patient (to clinic) with a diagnosis of persistent asthma or an established patient with uncontrolled persistent asthma and a clinical need for a new treatment regimen
- no history of having received a written AAP
- prescribed an inhaled corticosteroid (i.e., daily controller medication).
Exclusion Criteria
- patients and caregivers who do not use English as their primary language
- has a significant developmental (e.g., autism, intellectual disability) or sensory (e.g., blindness) disorder that would preclude completion of study measures.
Data sourced from ClinicalTrials.gov (NCT03187119). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.